Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Light Chain (al) Amyloidosis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for Light Chain (al) Amyloidosis. Eligibility criteria explained in plain English.

TrialFinderData lists 2 Light Chain (al) Amyloidosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Nanjing University School of Medicine (1), Nexcella Inc. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Dratumumab / Hyaluronidase Injection [Darzalex Faspro] (drug, 1 trial), followed by Pomalidomide 4 MG, autologous stem cell transplantation (ASCT).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
0
Phase 3 Trials
2
Sponsors

Track Light Chain (al) Amyloidosis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06376214

Daratumumab for Patients With Light Chain Amyloidosis

This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were...

Sponsor: Nanjing University School of MedicineEnrolling: 1001 location
RECRUITINGPhase 1 / Phase 2NCT06097832

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

Sponsor: Nexcella Inc.Enrolling: 4018 locations

Frequently Asked Questions

There are currently 2 clinical trials for Light Chain (al) Amyloidosis, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Light Chain (al) Amyloidosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Light Chain (al) Amyloidosis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.